Supplementary Figures from A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers

Supplementary Figure S1. Expression of BCL2L1 and BCL2 in CRC cell lines; Supplementary Figure S2. Estimated BCL2L1 copy numbers of CRC patients by droplet digital PCR (ddPCR); Supplementary Figure S3. Screening of MCL1-modulating agents for synergistic effect with ABT- 263 in KRAS-mutated and BCL2L1-amplified CRC cells (SW620); Supplementary Figure S4. Screening of MCL1-modulating agents for synergistic effect with ABT- 263 in KRAS wild and BCL2L1-diploid CRC cells (SNU1684); Supplementary Figure S5. Effect of ABT-263 and YM-155 combination treatment in CRC cell lines with different KRAS/BRAF mutation status and BCL2L1 copy numbers; Supplementary Figure S6. Effect of ABT-263 and YM-155 in siBCL2L1-treated SW620 cells; Supplementary Figure S7. The quantification of MCL1 protein expression and levels of cleaved caspase 3 and cleaved PARP from Figure 2; Supplementary Figure S8. The quantification of MCL1 protein expression and levels of cleaved caspase 3 and cleaved PARP from Supplementary Figure S5; Supplementary Figure S9. Estimation of apoptosis induced by combination of ABT-263 and YM- 155; Supplementary Figure S10. The quantification of protein expression levels from Figure 3; Supplementary Figure S11. The quantification of protein expression levels from Figure 4; Supplementary Figure S12. The quantification of protein expression levels from Figure 5; Supplementary Figure S13. In vivo efficacy of ABT-263 and YM-155 treatment in CRC cell line xenograft models.